Physician profile
Erin Flaherty
NPI 1568163525
$1,966.54
in general payments reported to CMS, 2019-2025
18 companies · $849 in 2025
The $849 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $439 · 2024: $678 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602.05 | 2023-2025 | |
| Novo Nordisk INC | $193.09 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $161.53 | 2023-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $116.97 | 2024 | Breztri |
| Inspire Medical Systems, INC. | $115.67 | 2024-2025 | Inspire |
| Pfizer INC. | $110.27 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.31 | 2023-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $95.17 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $90.46 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $79.78 | 2023 | Nuedexta |
| Exact Sciences Corporation | $53.48 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $50.50 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $47.43 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $43.64 | 2023 | |
| Verona Pharma, INC. | $31.09 | 2025 | Ohtuvayre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.29 | 2025 | Eliquis |
| Lundbeck LLC | $23.64 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $16.17 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.